Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose PK/PD and safety study of RO7434656 in Japanese healthy volunteers
jRCT2031230387Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sefaxersen (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics of RO7434656, Pharmacodynamics of RO7434656 and 1 more. Started Feb 2024; status: completed.
02
Drugs
sefaxersen
Beyond the preview
Go deeper on jRCT2031230387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230387.